KINNATE BIOPHARMA INC.
KNTE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for KNTE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2023.
Tracking 2 pipeline candidates · 1 clinical trial for KINNATE BIOPHARMA INC..
Run KINNATE BIOPHARMA INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available KINNATE BIOPHARMA INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
26.0 months
D/E 0.09
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is KINNATE BIOPHARMA INC.'s lead drug candidate?
KINNATE BIOPHARMA INC.'s most advanced tracked candidate is kin-2787 (Phase 1) for lung cancer, melanoma and other solid tumors.
Who is the CEO of KINNATE BIOPHARMA INC.?
Nima Farzan is the chief executive officer of KINNATE BIOPHARMA INC. (KNTE).
What therapeutic areas does KINNATE BIOPHARMA INC. focus on?
KINNATE BIOPHARMA INC. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.